Implementing non-invasive markers for liver fibrosis in clinical practice.
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
Noninvasive Assessment of Liver Fibrosis.
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
